KOL Perception of Microbiome Therapy in the U.S. |Survey Insights

1. Awareness & Understanding

Objective: Assess familiarity with microbiome-based therapies

Q1. How would you rate your familiarity with microbiome therapies?

Very familiar9

Moderately familiar11

Slightly familiar5

Not familiar0

→ 80% (20/25) have moderate to high familiarity → Indicates strong baseline awareness among KOLs

2. Perceived Clinical Potential

Objective: Evaluate belief in therapeutic value

Q2. How promising are microbiome therapies across indications?

Highly promising14

Moderately promising8

Slightly promising3

→ 88% positive sentiment → Strong confidence, especially in GI disorders and emerging systemic applications

3. Key Indications Identified

Objective: Identify priority disease areas

Q3. Which indications show the most promise? (Multiple responses allowed)

C. difficile infection22

Inflammatory bowel disease (IBD)18

Oncology (adjunct therapy)12

Metabolic disorders10

Neurological disorders6

→ C. difficile dominates as established use case → IBD and oncology seen as high-growth areas

4. Safety Perception

Objective: Understand safety concerns

Q4. How do you perceive the safety of microbiome therapies?

Very safe6

Generally safe with concerns15

Significant safety concerns4

→ 76% see therapies as safe but with caution → Key concerns: long-term effects, off-target microbiome changes

5. Regulatory Confidence

Objective: Gauge trust in regulatory pathway

Q5. How clear is the regulatory pathway in the U.S.?

Very clear3

Somewhat clear12

Unclear10

→ 40% perceive regulatory uncertainty → Seen as a barrier to broader adoption

6. Adoption Willingness

Objective: Measure likelihood of clinical use

Q6. How likely are you to prescribe/recommend microbiome therapies?

Very likely10

Likely9

Neutral4

Unlikely2

→ 76% willing to adopt → Adoption tied to stronger clinical evidence

7. Evidence Expectations

Objective: Identify evidence requirements

Q7. What level of evidence is needed for routine adoption?

Large Phase III trials17

Real-world evidence13

Mechanistic understanding9

→ Clinical trial data is the primary driver → Real-world data also highly valued

8. Key Barriers

Objective: Identify challenges to adoption

Q8. What are the biggest barriers? (Multiple responses)

Limited long-term data19

Regulatory ambiguity15

Manufacturing consistency14

Cost/reimbursement11

→ Evidence gap is the #1 barrier → Followed by regulatory and production challenges

9. Competitive Landscape Perception

Objective: Understand how crowded/competitive the field is

Q9. How competitive is the microbiome therapy space?

Highly competitive8

Moderately competitive13

Early-stage4

→ Seen as emerging but increasingly competitive

10. Future Outlook (5–10 years)

Objective: Capture long-term expectations

Q10. What is your outlook for microbiome therapies?

Transformational11

Significant niche role10

Limited impact4

→ 84% expect meaningful clinical impact → Split between "transformational" vs "targeted/niche"

Key Insights

High awareness + strong optimism among U.S. KOLs

C. difficile = anchor indication, validates platform credibility

Evidence and regulation = key bottlenecks

Adoption likely to accelerate with Phase III success and clearer FDA pathways

Field transitioning from experimental → clinically credible

Download Full Report (PDF)

KOL Perception: Microbiome Therapy

Key Insights

Trusted by Industry Leaders

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets

Key Insights

Trusted by Industry Leaders

Your Competitive Advantage inPharmaceutical & Medical TechnologyMarkets

Cookie Policy Overview

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets